Introduction: Workers in physically demanding jobs with high injury rates, long hours, productivity pressures, and lack of job security, such as commercial fishing, are at higher risk for substance use and misuse. In the United States, the federal government is urging employers to consider having naloxone available to reverse the effects of an opioid overdose, especially in workplaces. This study examined naloxone training, naloxone availability, and level of concern over substance use in commercial fishing.

Methods: As part of a larger study of commercial fishing vessel captains, we asked participants how worried they are about various potential problems, including substance use by crew members, using a five-point scale. We also asked whether they had completed naloxone training and whether their vessel was equipped with naloxone.

Results: Of the 61 vessel captains who participated, 10 had naloxone training. Most were "not at all worried" about a crew member misusing alcohol (n = 52; 85.2%), a crew member using marijuana (n = 50; 82.0%), a crew member using other drugs (n = 49; 80.3%), or a crew member having a drug overdose (n = 52; 86.7%). Only five fishing vessels were equipped with naloxone.

Conclusion: Our results indicate that few fishing vessels are equipped with naloxone or have captains trained in its use. Fishing captains tend not to be worried about substance use in their crew. Given the higher rate of overdose deaths in the fishing industry compared to other industries, having more vessels equipped with naloxone and captains trained to administer it could save lives.

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajim.23491DOI Listing

Publication Analysis

Top Keywords

naloxone training
16
crew member
16
commercial fishing
12
vessels equipped
12
naloxone
8
fishing industry
8
vessel captains
8
substance crew
8
fishing vessels
8
equipped naloxone
8

Similar Publications

Tramadol as a fentanyl adulterant: Prevalence and management in a ToxIC Fentalog study prospective cohort.

Am J Emerg Med

December 2024

Icahn School of Medicine at Mount Sinai, Center for Research on Emerging Substances, Poisoning, Overdose, and New Discoveries (RESPOND), NYC Health + Hospitals/Elmhurst, New York, NY, USA.

Background: Tramadol is an adulterant of illicit opioids. As it is a serotonin-norepinephrine reuptake inhibitor as well as a μ-opioid agonist, tramadol adulteration may worsen overdose signs and symptoms or affect the amount of naloxone patients receive.

Methods: This is a multicenter, prospective cohort of adult patients with suspected opioid overdoses who presented to one of eight United States emergency departments and were included in the Toxicology Investigators Consortium's Fentalog Study.

View Article and Find Full Text PDF

Trends in naloxone co-prescriptions.

Drug Alcohol Depend

December 2024

Stanford University School of Medicine, Office of PA Education, 300 Pasteur Drive, Stanford, CA, United States; Stanford University School of Medicine, Department of Medicine, Division of Primary Care and Population Health, 300 Pasteur Drive, Stanford, CA, United States; Kaiser Permanente Mountain View Medical Offices, Department of Internal Medicine, 555 Castro Street, Mountain View, CA, United States. Electronic address:

Background: The opioid epidemic remains a significant public health crisis in the United States. Naloxone has been identified as a critical component in combating this crisis. However, co-prescription rates among patients receiving opioids remain suboptimal, especially among certain high-risk populations.

View Article and Find Full Text PDF

Morphine belongs to the class of opioids and is known for its potential to cause dependence and addiction, particularly with prolonged use. Due to the associated risks, caution must be taken when prescribing and limiting its clinical use. Overexpression of N-methyl-D-aspartate (NMDA) receptors, nitric oxide and cGMP pathway has been implicated in exacerbate the development of morphine dependence and withdrawal.

View Article and Find Full Text PDF

Understanding the financial barriers to treatment among individuals with opioid use disorder: a focus group study.

Harm Reduct J

December 2024

Department of Pharmaceutical Health Outcomes and Policy, University of Houston College of Pharmacy, Health 2 Building, 4349 Martin Luther King Boulevard, Houston, TX, 77204-5047, USA.

Introduction: Despite the established effectiveness and relatively widespread availability of Medications for Opioid Use Disorder, individuals seeking treatment frequently encounter various structural and social barriers, including costs of treatment. This study aimed to understand the financial barriers that affect treatment continuation in individuals with opioid use disorder (OUD).

Methods: In this qualitative study, seven semi-structured in-depth focus group interviews were conducted among 28 participants in treatment for OUD.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!